A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB019 in Healthy Subjects and Psoriasis Patients.
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
At a glance
- Drugs ANB 019 (Primary) ; ANB 019 (Primary)
- Indications Generalised pustular psoriasis; Palmoplantar pustulosis; Plaque psoriasis
- Focus Adverse reactions; First in man
- Sponsors AnaptysBio
- 06 Apr 2017 Status changed from not yet recruiting to recruiting, according to an AnaptysBio Inc. media release.
- 15 Mar 2017 Status changed from planning to not yet recruiting.
- 11 Mar 2017 New trial record